Inter-tumor heterogeneity of PD-L1 expression in non-small cell lung cancer

BACKGROUND: The Dako PD-L1 immunohistochemistry (IHC) 22C3 pharmDx and the Dako 28-8 IHC pharmDx assays were approved by the US Food and Drug Administration, as a companion diagnostic test for pembrolizumab (Keytruda, Merk, Kenilworth, NJ, USA) and a complementary diagnostic test for nivolumab (Opdi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Thorac Dis
Main Authors: Saito, Yuichi, Horiuchi, Sho, Morooka, Hiroaki, Ibi, Takayuki, Takahashi, Nobumasa, Ikeya, Tomohiko, Shimizu, Yoshihiko, Hoshi, Eishin
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6988081/
https://ncbi.nlm.nih.gov/pubmed/32030214
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2019.12.24
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados